Global Partners LP

1 day ago · fool.com

Novo Nordisk is one of two leading GLP-1 producers. The company is cutting prices on its GLP-1 drugs as it shifts toward a volume-driven model.

2 days ago · fool.com

VanEck Pharmaceutical ETF provides a higher dividend yield and lower price volatility compared to the State Street fund. State Street SPDR Pharmaceuticals ETF offers a more diversified portfolio with more than twice as many individual holdings.

3 days ago · seekingalpha.com

Viking Therapeutics, Inc. is advancing VK2735, a dual GLP-1/GIP agonist, targeting the obesity and diabetes market dominated by Eli Lilly and Novo Nordisk. VKTX's Phase 3 VANQUISH trials for injectable VK2735, and SUNRISE trials for oral VK2735, are key 2025–2027 catalysts; >20% weight loss with strong safety could drive approval. Recent maintenance study data showed up to 21.7% mean weight loss and excellent tolerability with less frequent dosing, but competition and limited data durability remain concerns.

4 days ago · globenewswire.com

Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain One-third of surveyed GLP-1 users expressed a preference for an endoscopic procedure over continued GLP-1 medication A one-time procedure and freedom from daily or weekly medication were the most frequently selected positive attributes, supporting commercial planning for Revita BURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced findings from company-sponsored market research highlighting strong patient interest in a one-time procedural approach to weight maintenance following GLP-1 therapy.

5 days ago · benzinga.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released results from its Phase 3 trial evaluating Nereus, an oral therapy aimed at preventing vomiting associated with GLP-1 receptor agonist treatments.

6 days ago · businesswire.com

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River announces that its VCG database and methodology, designed to reduce animal use, will be used in an upcoming GLP study for Ipsen.

6 days ago · prnewswire.com

NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative reduction Vomiting + severe nausea (key secondary): 33.1% (47/142) vs 50.6% (83/164) (p=0.002); 35% relative reduction Frequent multi-day vomiting (>2 episodes on more than one day): 6.3% (9/142) vs 15.9% (26/164) (p=0.008); 60% relative reduction Extreme vomiting (>10 total episodes): 2.8% (4/142) vs 14.6% (24/164) (p=0.0003); 81% relative reduction WASHINGTON, Oct. 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive results from Study 3601 (VP-VLY-686-3601), a Phase III randomized, placebo-controlled study evaluating NEREUS™ (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting associated with GLP-1 receptor agonist therapy. The study showed significant reduction in overall vomiting episodes (27% p=0.006 as well as reduction of frequent (60% p=0.008) and extreme vomiting (81% p=0.0003) episodes.

11 days ago · etftrends.com

GLP-1 drugs have put peptides on investors' radar, with Eli Lilly (LLY) and Novo Nordisk (NVO) leading the weight-loss market. But the investment opportunity extends beyond these treatments.

11 days ago · newsfilecorp.com

Four U.S.-made transdermal peptide patches, one manufacturer, one brand: BPC-157 on sale, 20,000 TA1 units in production, Tirzepatide and GLP3 in development Highlights Exclusive manufacturing rights secured for all four of the Company's patch formulations: BPC-157, Thymosin Alpha-1 (TA1), tirzepatide and GLP3 Four patches, one U.S. manufacturer, one brand: each patch produced solely for The Precision Peptide Company The Recovery Patch (BPC-157) is on sale now; 20,000 TA1 patches ordered, with delivery expected in January 2027 No needle, no mixing, no measuring, no refrigeration 100% manufactured and tested in the United States To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/8944/320328_fb299fe9347c78d6_002full.jpg Vancouver, British Columbia--(Newsfile Corp. - October 22, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company") or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announced that it has secured exclusive manufacturing rights from its U.S. manufacturer to all four of its patch formulations: BPC-157, Thymosin Alpha-1 ("TA1"), Tirzepatide and GLP3 transdermal patch ("GLP3"). Each patch will be produced solely for The Precision Peptide Company.

11 days ago · globenewswire.com

Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce reduction aligns organization behind Revita's near-term clinical and commercial opportunity Company discontinuing development of Rejuva candidates and seeking strategic alternatives to maximize the value of its Rejuva gene therapy program Cash runway extended into Q2 2027; quarterly operating cash burn expected to be reduced by ~50% to approximately $8 million by end of Q2 2027 BURLINGTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it is sharpening its focus and concentrating its financial and operational resources on advancing Revita®, its lead product candidate, toward potential U.S. Food and Drug Administration (FDA) marketing authorization and commercialization in post-GLP-1 weight maintenance.